fda enforcement actions bpc-157 tb-500 statement bpc 157 The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies A step towards expanded patient

AOD-9604 2mg is a synthetic peptide derived from a specific segment of human growth hormone

Persistent or severe headaches warrant discontinuation and medical evaluation

BPC-157 : TB500 (Thymosin Beta 4) : BPC-157 & TB500 (Thymosin Beta 4) CERTIFICATES OF ANALYSIS 6 COAs BN-26BT11-001 Current Variant: Size: 10mg-10mg BPC-157 11.7 mg / 11.85 mg TB-500 11.54 mg / 11.44 mg BN-25BT55-004 Current Variant: Size: 5mg-5mg BPC-157 5.89 mg / 5.73 mg TB-500 5.68 mg / 5.57 mg BN-24BT55 Upcoming Variant: Size: 5mg-5mg BPC-157 5.57 mg TB-500 5.49 mg BN-25BT11-002 Previous Variant: Size: 10mg-10mg BN-25BT11-001 Previous Variant: Size: 10mg-10mg BN-24BT55-001 Previous Variant: 5 mg / 5 mg Formulation BPC-157 and TB-500 (Thymosin Beta-4) are research peptides supplied for use in controlled laboratory and analytical environments

Ketorolac was approved by the FDA for parenteral use in November 1989, oral use in December 1991, ophthalmic use in November 1992, and intranasal use in May 2010